106 related articles for article (PubMed ID: 25702420)
1. Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: biological effects on human tumor cells.
Kuznetsova NR; Svirshchevskaya EV; Sitnikov NS; Abodo L; Sutorius H; Zapke J; Velder J; Thomopoulou P; Oschkinat H; Prokop A; Schmalz HG; Fedorov AY; Vodovozova EL
Bioorg Khim; 2013; 39(5):609-18. PubMed ID: 25702420
[TBL] [Abstract][Full Text] [Related]
2. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics.
Crielaard BJ; van der Wal S; Le HT; Bode AT; Lammers T; Hennink WE; Schiffelers RM; Fens MH; Storm G
Eur J Pharm Sci; 2012 Mar; 45(4):429-35. PubMed ID: 21907797
[TBL] [Abstract][Full Text] [Related]
3. [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
Mouseeva EV; Kuznetsova NR; Svirshchevskaia EV; Bovin NV; Sitnikov NC; Shavyrin AS; Beletskaia IP; Combes S; Fedorov AIu; Vodovozova EL
Biomed Khim; 2012; 58(3):326-38. PubMed ID: 22856138
[TBL] [Abstract][Full Text] [Related]
4. Design and preparation of pH-sensitive cytotoxic liposomal formulations containing antitumor colchicine analogues for target release.
Shchegravina ES; Tretiakova DS; Sitdikova AR; Usova SD; Boldyrev IA; Alekseeva AS; Svirshchevskaya EV; Vodovozova EL; Fedorov AY
J Liposome Res; 2024 Sep; 34(3):399-410. PubMed ID: 37867342
[TBL] [Abstract][Full Text] [Related]
5. Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma.
Alekseeva AA; Moiseeva EV; Onishchenko NR; Boldyrev IA; Singin AS; Budko AP; Shprakh ZS; Molotkovsky JG; Vodovozova EL
Int J Nanomedicine; 2017; 12():3735-3749. PubMed ID: 28553111
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Formulation of a PLA2-Sensitive Phospholipid-Allocolchicinoid Conjugate: Stability and Activity Studies In Vitro.
Kobanenko MK; Tretiakova DS; Shchegravina ES; Antipova NV; Boldyrev IA; Fedorov AY; Vodovozova EL; Onishchenko NR
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162957
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
8. Phospholipidic Colchicinoids as Promising Prodrugs Incorporated into Enzyme-Responsive Liposomes: Chemical, Biophysical, and Enzymological Aspects.
Shchegravina ES; Tretiakova DS; Alekseeva AS; Galimzyanov TR; Utkin YN; Ermakov YA; Svirshchevskaya EV; Negrebetsky VV; Karpechenko NY; Chernikov VP; Onishchenko NR; Vodovozova EL; Fedorov AY; Boldyrev IA
Bioconjug Chem; 2019 Apr; 30(4):1098-1113. PubMed ID: 30817133
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation.
Fournier-Dit-Chabert J; Vinader V; Santos AR; Redondo-Horcajo M; Dreneau A; Basak R; Cosentino L; Marston G; Abdel-Rahman H; Loadman PM; Shnyder SD; Díaz JF; Barasoain I; Falconer RA; Pors K
Bioorg Med Chem Lett; 2012 Dec; 22(24):7693-6. PubMed ID: 23103097
[TBL] [Abstract][Full Text] [Related]
10. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer.
Kuznetsova NR; Sevrin C; Lespineux D; Bovin NV; Vodovozova EL; Mészáros T; Szebeni J; Grandfils C
J Control Release; 2012 Jun; 160(2):394-400. PubMed ID: 22210161
[TBL] [Abstract][Full Text] [Related]
11. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
12. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
13. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
[TBL] [Abstract][Full Text] [Related]
14. Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.
Kuznetsova NR; Vodovozova EL
Biochemistry (Mosc); 2014 Aug; 79(8):797-804. PubMed ID: 25365489
[TBL] [Abstract][Full Text] [Related]
15. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
16. Anticancer double lipid prodrugs: liposomal preparation and characterization.
Arouri A; Mouritsen OG
J Liposome Res; 2011 Dec; 21(4):296-305. PubMed ID: 21438721
[TBL] [Abstract][Full Text] [Related]
17. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.
Tretiakova D; Svirshchevskaya E; Onishchenko N; Alekseeva A; Boldyrev I; Kamyshinsky R; Natykan A; Lokhmotov A; Arantseva D; Shobolov D; Vodovozova E
Curr Drug Deliv; 2020; 17(4):312-323. PubMed ID: 32056524
[TBL] [Abstract][Full Text] [Related]
19. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.
Crielaard BJ; van der Wal S; Lammers T; Le HT; Hennink WE; Schiffelers RM; Storm G; Fens MH
Int J Nanomedicine; 2011; 6():2697-703. PubMed ID: 22114500
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
